DR. HELLA KOHLHOF

Dr. Hella Kohlhof is the CSO of Immunic AG and Managing Director of Immunic's research subsidiary, Immunic Research GmbH, Halle (Saale). She joined Immunic in January 2017 from 4SC AG, a publicly listed German biotech company where she was responsible for the management of the clinical product portfolio.

Hella Kohlhof studied biology in Aachen, Gothenburg (Sweden) and Munich and received her Doctorate in Biology from the Ludwig Maximilians University of Munich (Germany). During her Ph.D. and PostDoc position at the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich, she worked on normal and malignant B cell development influenced by Notch and Epstein Barr Virus mediated signaling.

In 2008, she joined 4SC AG as a research scientist and group leader and established the research laboratory for translational pharmacology. She worked on 4SC's preclinical and clinical stage projects in the oncology and immunology field, including IMU-838 and IMU-935. From 2011 on, Hella was responsible for the management and development of 4SC's epigenetic clinical stage small molecule inhibitor 4SC-202.

In early 2015, as Director Development Projects, she took over responsibility for the complete development portfolio of 4SC AG. Hella has a very strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational pharmacology, clinical trial design and biomarker development.

She has been invited speaker at international conferences and is owner of several patents and co-author of a book chapter and several scientific publications.

SHORT BIO

SKILLS	EXPERIENCE	QUALIFICATION	MOTIVATION
Transition of preclinical to clinical stage products	Drug development, preclinical and translational pharmacology, clinical trial design, biomarker development	Experienced in preclinical research up to managing the development portfolio at 4SC	Developing state-of-the-art treatments of autoimmune diseases